New Blog - Inflation Rebate Proposal Builds on Bad Policy for Generics

Congress Needs To Hear From You!

Lawmakers are actively considering prescription drug reforms included in the Build Back Better Act (H.R. 5376) that would undermine patient access to affordable FDA-approved generic and biosimilar medicines. Tell your Senator not to put these medicines at risk!

Take Action!
AAM Encourages Congress to Protect Patient Savings

Competition from lower-cost generics and biosimilars has successfully led to decades of savings for patients. AAM strongly opposes negotiations in Medicare that would jeopardize these savings.

Learn More
Featured AAM All Access Podcast: Bob Pollock

Lachman Consultants Senior Advisor Robert (Bob) Pollock shares his experiences at FDA in the early days of the generics industry, the backbone of today's pharmaceutical business.

Listen to Podcast
Access! 2022

Access! brings together policymakers, influential speakers and industry leaders to chart the future of generics and biosimilars. Plan to join us in person for the first time since 2019 in Orlando!  Early bird $500 savings off full-pass registration available until December 31, 2021.

Register Today
2021 U.S. Generic and Biosimilar Medicines Savings Report

Report reveals continued savings growth through lower-cost generic and biosimilar competition. The findings reinforce the outsized importance of the industry delivering lifesaving & health-managing medicines.

View Full Report
Patient Stories: Voices of Access

AAM's Voices of Access report features patients across the country who tell the impact of accessible generic and biosimilar medicines.

Meet the AAM Patients

Working to leave a positive impact on...

Industry

We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers of generic and biosimilar medicines and combatting anti-competitive abuses by some brand drug companies who put profits before patients. Learn More

People

We measure our success as an industry by the lives we impact. We work to protect the low cost of generic and biosimilar medicines and to drive down the cost of developing new ones, expanding access to as many people as possible. Learn More

Policy

We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable generic and biosimilar medicines. Learn More

About Us

The Association for Accessible Medicines improves access to safe, quality, effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

Recent Updates

Female pharmacist services senior female customer buying prescription medicine package and paying using contactless method

Nov 15, 2021 | Craig Burton

Inflation Rebate Proposal Builds on Bad Policy for Generics

Dr. Robert Califf

Nov 12, 2021 | Rachel Schwartz

AAM Statement on the Nomination of Dr. Robert Califf to Lead FDA

HHS Proposal Will Help America’s Patients Realize the Full Value of Their Generics and Biosimilars

Nov 12, 2021 | Monét Stanford

Medicare Negotiations Serve as a Catalyst to a Perpetual Monopoly

Nov 10, 2021 | Rachel Schwartz

Paula Witt Joins AAM as Senior Manager, State Government Affairs

Misguided Drug Pricing Reform

Nov 2, 2021 | Rachel Schwartz

AAM Opposes Latest Prescription Drug Reform Framework

Cover of A Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain

Nov 2, 2021 | Jonathan Kimball

Second Edition of AAM’s Blueprint to Enhance the Security of the U.S. Pharmaceutical Supply Chain